<DOC>
	<DOCNO>NCT01707992</DOCNO>
	<brief_summary>This multinational , multicenter , randomize , double-blind , parallel-group , placebo-controlled study follow active treatment , evaluate efficacy , safety tolerability two dose oral administration laquinimod 0.6 mg/day 1.2mg/day subject RRMS .</brief_summary>
	<brief_title>The Efficacy Safety Tolerability Laquinimod Subjects With Relapsing Remitting Multiple Sclerosis ( RRMS )</brief_title>
	<detailed_description>Eligible subject confirm relapsing-remitting multiple sclerosis randomize 1:1:1 ratio one follow treatment arm : Laquinimod capsule 0.6 mg , Laquinimod capsule 1.2 mg match placebo . The study comprise two treatment period : Period 1 : Double-blind Placebo-controlled ( DBPC ) period : 24 month once-daily , oral administration either laquinimod 0.6 mg , 1.2 mg match oral placebo . The Sponsor declare close Period 1 subject 260 event confirm disease progression ( CDP ) occur ongoing enrol subject complete 24 month Period 1 ( whichever occurs first ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Subjects must confirm documented MS diagnosis define Revised McDonald criterion , relapse onset disease relapsingremitting disease course . Subjects must ambulatory Kurtzke EDSS score 0 5.5 screen randomization visit . Subjects must stable neurological condition , relapsefree free corticosteroid treatment [ intravenous ( IV ) , intramuscular ( IM ) and/or per o ( PO ) ] adrenocorticotrophic hormone ( ACTH ) , 60 day prior randomization . Subjects must experience least one document relapse 12 month prior randomization . Subjects must 18 55 year age screening , inclusive . Subjects must disease duration 15 year . Women childbearing potential ( example woman postmenopausal surgically sterilize ) must practice acceptable method birth control 30 day take study drug two acceptable method birth control duration study 30 day last dose study medication . Acceptable method birth control include : intrauterine device , barrier method ( condom diaphragm spermicide ) hormonal method birth control ( e.g . oral contraceptive , contraceptive patch , longacting injectable contraceptive ) . Subjects must able sign date write informed consent prior enter study . Subjects must willing able comply protocol requirement duration study . Subjects progressive form MS . Subjects Neuromyelitis Optica ( NMO ) . Use experimental investigational drug and/or participation drug clinical study within 6 month prior randomization . Use immunosuppressive agent , cytotoxic agent , include Cyclophosphamide within 6 month prior randomization . Use either follow within 2 year prior screen visit : natalizumab ( Tysabri® ) , rituximab , ocrelizumab , atacicept , belimumab , ofatumumab . Use teriflunomide ( Aubagio® ) within 2 year prior randomization , except active washout ( either cholestyramine activated charcoal ) do 2 month prior randomization . Previous treatment glatiramer acetate ( Copaxone® ) Interferon β ( either 1a 1b ) , fingolimod ( Gilenya® ) , dimethyl fumarate ( Tecfidera® ) intravenous immunoglobulin ( IVIG ) within 2 month prior randomization . Chronic ( 30 consecutive day ) systemic ( IV , IM PO ) corticosteroid treatment within 2 month prior randomization . Previous use Mitoxantrone ( Novantrone® ) , Cladribine , alemtuzumab ( Lemtrada® ) . Previous use laquinimod . Previous total body irradiation total lymphoid irradiation . Previous stem cell treatment , autologous bone marrow transplantation allogenic bone marrow transplantation . Use moderate/strong inhibitor CYP3A4 within 2 week prior randomization . Use inducer CYP3A4 within 2 week prior randomization . Pregnancy breastfeed . Serum level ≥3x upper limit normal range ( ULN ) either alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) screen Serum direct bilirubin ≥2xULN screen . Subjects clinically significant unstable medical surgical condition condition wellcontrolled allow medication permit study protocol would preclude safe complete study participation , determine medical history , physical examination , ECG , laboratory test MRI chest Xray . Such condition may include : A major cardiovascular event ( e.g . myocardial infarction , acute coronary syndrome , decompensated congestive heart failure , pulmonary embolism , coronary revascularization ) occur past 6 month prior randomization . Any acute pulmonary disorder A CNS disorder MS may jeopardize subject 's participation study , include disorder demonstrate baseline MRI . A gastrointestinal disorder may affect absorption study medication . Renal disease . Any form acute chronic liver disease . Known human immunodeficiency virus positive status . A history drug and/or alcohol abuse . Unstable psychiatric disorder . Any malignancy , exclude basal cell carcinoma , 5 year prior randomization . A known history sensitivity gadolinium ( Gd ) . GFR ≤ 60 mL/min screen visit . Inability successfully undergo MRI scanning . Subjects underwent endovascular treatment Chronic Cerebrospinal Venous Insufficiency ( CCSVI ) within 3 month prior randomization . Known hypersensitivity would preclude administration laquinimod capsule , hypersensitivity : mannitol , meglumine sodium stearyl fumarate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>